Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Bromhexine  COVID-19 treatment studies for Bromhexine  C19 studies: Bromhexine  Bromhexine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Loading...
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Bromhexine for COVID-19: real-time meta analysis of 6 studies
Covid Analysis, June 23, 2022, DRAFT
https://c19bromhexine.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ansarin (RCT) 91% 0.09 [0.01-1.59] 24mg death 0/39 5/39 Improvement, RR [CI] Dose (1d) Treatment Control Ansarin (RCT) 89% 0.11 [0.01-0.84] 24mg ventilation 1/39 9/39 Ansarin (RCT) 82% 0.18 [0.04-0.77] 24mg ICU 2/39 11/39 Li (RCT) 75% 0.25 [0.06-1.00] 96mg no disch. 2/12 4/6 Li (RCT) 50% 0.50 [0.09-2.73] 96mg oxygen 2/12 2/6 Mareev (RCT) 11% 0.89 [0.65-1.22] 32mg no recov. 33 (n) 33 (n) CT​1 Mareev (RCT) 39% 0.61 [0.14-0.97] 32mg no disch. 14/24 20/21 CT​1 Mareev (RCT) 8% 0.92 [0.77-1.09] 32mg hosp. time 33 (n) 33 (n) CT​1 Mareev (RCT) 87% 0.13 [0.01-2.25] 32mg viral+ 0/17 3/13 CT​1 Tolouian (RCT) 76% 0.24 [0.01-8.03] 32mg death 48 (n) 52 (n) Tolouian (RCT) 76% 0.24 [0.01-7.69] 32mg no improv. 48 (n) 52 (n) Tolouian (RCT) -75% 1.75 [1.13-2.71] 32mg cases 29/48 18/52 Mikhaylov (RCT) 80% 0.20 [0.01-3.97] 24mg hosp. 0/25 2/25 Mikhaylov (RCT) 91% 0.09 [0.01-1.56] 24mg symp. case 0/25 5/25 Mikhaylov (RCT) 71% 0.29 [0.07-1.24] 24mg viral+ 2/25 7/25 Tolouian (DB RCT) 33% 0.67 [0.04-10.5] 24mg death 0/187 1/185 Tolouian (DB RCT) 70% 0.30 [0.05-1.78] 24mg hosp. 1/187 6/185 Tolouian (DB RCT) 53% 0.47 [0.25-0.87] 24mg symp. case 16/187 34/185 Tolouian (DB RCT) 50% 0.50 [0.24-0.99] 24mg cases 13/187 26/185 bromhexine COVID-19 outcomes c19bromhexine.com Jun 2022 1 CT: study uses combined treatment Favors bromhexine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit